Predicted probability of high adherence to maintenance treatments per posthoc simplified psoriatic arthritis model
| Treatment†‡ | Component being rated | Predicted high adherence* probability (% (95% CI)) in patients with PsA (n=635) | |||
| Short disease duration (<9 years) | Long disease duration (≥9 years) | ||||
| Low BMQ-General Harm Score (<12) | High BMQ-General Harm Score (≥12) | Low BMQ-General Harm Score (<12) | High BMQ-General Harm Score (≥12) | ||
| Age ≥51 years | |||||
| csDMARD-TNFi combination | TNFi | 95.1 (88.8 to 98.0) | 87.1 (74.7 to 93.9) | 90.1 (80.5 to 95.3) | 76.0 (59.2 to 87.4) |
| TNFi monotherapy | TNFi | 95.5 (89.4 to 98.2) | 88.0 (75.8 to 94.5) | 90.9 (81.8 to 95.6) | 77.5 (61.3 to 88.2) |
| csDMARD-TNFi combination | csDMARD | 87.9 (77.0 to 94.1) | 71.6 (54.3 to 84.3) | 77.3 (62.8 to 87.3) | 54.2 (36.0 to 71.3) |
| csDMARD monotherapy | csDMARD | 91.7 (83.7 to 96.0) | 79.4 (64.4 to 89.1) | 83.9 (71.3 to 91.6) | 64.3 (45.1 to 79.9) |
| Age <51 years | |||||
| csDMARD-TNFi combination | TNFi | 82.1 (69.2 to 90.3) | 61.4 (43.0 to 77.0) | 68.3 (51.3 to 81.4) | 42.7 (24.9 to 62.6) |
| TNFi monotherapy | TNFi | 83.3 (71.4 to 90.9) | 63.3 (45.7 to 78.0) | 70.0 (54.8 to 81.8) | 44.7 (27.6 to 63.2) |
| csDMARD-TNFi combination | csDMARD | 63.1 (47.2 to 76.6) | 37.2 (22.0 to 55.5) | 44.5 (28.5 to 61.7) | 21.7 (10.7 to 39.3) |
| csDMARD monotherapy | csDMARD | 72.3 (57.8 to 83.2) | 47.5 (30.0 to 65.6) | 55.0 (37.0 to 71.9) | 29.8 (14.9 to 50.6) |
*High/full medication adherence: 4-item Morisky Medication Adherence Scale©=4.
†With or without concomitant glucocorticoid.
‡Some combinations are not recommended according to the European League Against Rheumatism.41
BMQ, Beliefs about Medicines Questionnaire; PsA, psoriatic arthritis; TNFi, tumour necrosis factor inhibitor; csDMARD, conventional synthetic disease-modifying antirheumatic drug.